Neurocrine Biosciences, Inc.

NasdaqGS:NBIX Stock Report

Market Cap: US$15.3b

Neurocrine Biosciences Balance Sheet Health

Financial Health criteria checks 6/6

Neurocrine Biosciences has a total shareholder equity of $2.7B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $3.5B and $816.1M respectively. Neurocrine Biosciences's EBIT is $602.3M making its interest coverage ratio -6.9. It has cash and short-term investments of $1.2B.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ratio-6.9x
CashUS$1.23b
EquityUS$2.72b
Total liabilitiesUS$816.10m
Total assetsUS$3.54b

Recent financial health updates

Recent updates

Neurocrine Biosciences' Crenessity Approval Sets Stage For Diversified Revenue And Growth

Dec 18

Shareholders Should Be Pleased With Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price

Dec 09
Shareholders Should Be Pleased With Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price

Neurocrine: A Buy Amid CNS Pipeline Growth And Ingrezza's Strength (Rating Upgrade)

Oct 10

The Play On Neurocrine Biosciences

Oct 02

Neurocrine: Buying Opportunity After Stock Price Drop On Schizophrenia Data

Aug 28

Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Jul 28
Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Neurocrine's Pipeline, Including Crinecerfont's Priority Review, Drives Long-Term Growth

Jul 09

Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality

May 08
Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality

Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Apr 27
Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data

Apr 25

Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Mar 31
Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside

Feb 11

Financial Position Analysis

Short Term Liabilities: NBIX's short term assets ($1.9B) exceed its short term liabilities ($429.7M).

Long Term Liabilities: NBIX's short term assets ($1.9B) exceed its long term liabilities ($386.4M).


Debt to Equity History and Analysis

Debt Level: NBIX is debt free.

Reducing Debt: NBIX has no debt compared to 5 years ago when its debt to equity ratio was 70.2%.

Debt Coverage: NBIX has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: NBIX has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/06 05:03
End of Day Share Price 2025/02/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Neurocrine Biosciences, Inc. is covered by 42 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Martha FreitagArgus Research Company
Brian SkorneyBaird
Ishan MajumdarBaptista Research